Literature DB >> 7959183

Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group.

M B Menke-Pluymers1, A H Mulder, W C Hop, M van Blankenstein, H W Tilanus.   

Abstract

The role of dysplasia and aneuploidy as markers in columnar epithelium for malignant degeneration in Barrett's oesophagus was compared in a case control study comprising 38 patients with benign Barrett's oesophagus and 50 patients with Barrett's oesophagus associated with adenocarcinoma. Tissue specimens of columnar epithelium were reviewed for the presence of specialised columnar epithelium and the grade of dysplasia. Ploidy was determined using the method for formalin fixed paraffin wax embedded tissue described by Hedley. There was no significant difference in the frequency of specialised columnar epithelium between both groups. Dysplasia was found more often in columnar epithelium associated with adenocarcinoma compared with benign Barrett's oesophagus (p < 0.001). Multivariate analysis using logistic regression showed an increased risk of malignancy in Barrett's oesophagus in case of dysplasia (odds ratio 9.4, p = 0.003 for mild dysplasia and 33.1, p < 0.001 for moderate or severe dysplasia). Ploidy was not statistically significantly correlated with dysplasia. Aneuploidy or increased G2/tetraploidy proved to be an independent risk factor for younger patients (age < 65 years: odds ratio 44.7, p = 0.003). In conclusion, dysplasia and aneuploidy or increased G2/tetraploidy in columnar epithelium are independent risk factors for malignant degeneration. Patients with these risk factors should be offered a more intensive screening programme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7959183      PMCID: PMC1375001          DOI: 10.1136/gut.35.10.1348

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  The lower esophagus lined by columnar epithelium.

Authors:  N R BARRETT
Journal:  Surgery       Date:  1957-06       Impact factor: 3.982

2.  The histologic spectrum of Barrett's esophagus.

Authors:  A Paull; J S Trier; M D Dalton; R C Camp; P Loeb; R K Goyal
Journal:  N Engl J Med       Date:  1976-08-26       Impact factor: 91.245

3.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

4.  Progression to cancer in Barrett's esophagus is associated with genomic instability.

Authors:  P S Rabinovitch; B J Reid; R C Haggitt; T H Norwood; C E Rubin
Journal:  Lab Invest       Date:  1989-01       Impact factor: 5.662

5.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

Authors:  A J Cameron; B J Ott; W S Payne
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

6.  Dysplasia in Barrett's esophagus.

Authors:  H G Schmidt; R H Riddell; B Walther; D B Skinner; J F Riemann
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

8.  Clinical significance of abnormal nuclear DNA content in serous ovarian tumors.

Authors:  P J Klemi; H Joensuu; P Kiilholma; J Mäenpää
Journal:  Cancer       Date:  1988-11-01       Impact factor: 6.860

9.  The influence of age on the DNA ploidy levels of breast tumours.

Authors:  I W Taylor; E A Musgrove; M L Friedlander; M S Foo; D W Hedley
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

10.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.

Authors:  B J Reid; R C Haggitt; C E Rubin; P S Rabinovitch
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

View more
  12 in total

1.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Epithelial cell proliferative activity of Barrett's esophagus: methodology and correlation with traditional cancer risk markers.

Authors:  F T Peters; S Ganesh; E J Kuipers; A de Jager-Krikken; A Karrenbeld; G Harms; W J Sluiter; J Koudstaal; E C Klinkenberg-Knol; C B Lamers; J H Kleibeuker
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

Review 4.  Natural history of Barrett's esophagus.

Authors:  Rao Milind; Stephen E Attwood
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 5.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.

Authors:  S R DeMeester; T R DeMeester
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

6.  Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study.

Authors:  J C Mendes de Almeida; P Chaves; A D Pereira; N K Altorki
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

7.  Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.

Authors:  Andreas Weimann; Anja Rieger; Mathias Zimmermann; Monica Gross; Peter Hoffmann; Hortense Slevogt; Lars Morawietz
Journal:  Virchows Arch       Date:  2010-09-16       Impact factor: 4.064

8.  c-Myc-mediated genomic instability proceeds via a megakaryocytic endomitosis pathway involving Gp1balpha.

Authors:  Youjun Li; Jie Lu; Edward V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

9.  Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.

Authors:  L J Williams; D L Guernsey; A G Casson
Journal:  Curr Oncol       Date:  2006-02       Impact factor: 3.677

10.  NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Authors:  Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.